Skip to main content

Month: July 2020

NexTech AR Launches New Interactive ‘ScreenAR’ Video Conferencing and Virtual Events Solutions

SANTA CRUZ, Calif. and TORONTO, July 17, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality for eCommerce, AR learning applications, and AR-enhanced video conferencing and virtual events is pleased to announce that it has launched a new immersive video conferencing software called ScreenAR. The new capabilities are seamlessly integrated into its InfernoAR platform using its ARitize app. The new AR features will allow for AR experiences to “pop” off the computer screen creating a one-of-a-kind immersive experience that everyone is craving today. This new capability is aiming to keep people engaged in virtual classrooms, virtual events, or virtual trade shows, becoming the video conferencing industry standard.SEE DEMO VIDEO HEREThe ScreenAR will work...

Continue reading

Medigus to Resell Polyrizon’s Future Products for Protection Against COVID-19 Spread and Other Biological Threats

The companies signed investment and reseller agreements for joint commercializationOMER, Israel, July 17, 2020 (GLOBE NEWSWIRE) —  Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced the signing of an investment agreement and a reseller agreement with Polyrizon Ltd., a private company engaged in developing biological gels for the purpose of protecting patients against biological threats.As part of the reseller agreement Medigus receives an exclusive global license to resell the Polyrizon products, focusing on a unique Biogel for the protection from COVID-19 virus. The term of the license will be for four years, commencing upon receipt of sufficient FDA approvals for the lawful marketing and sale of the products globally....

Continue reading

MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients  

• Data being presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting • Significant improvements demonstrated after treatment in Phase 1/2 clinical trial • Based on encouraging safety and efficacy profile, MeiraGTx and Janssen expect to progress AAV-RPGR into Phase 3 Lumeos clinical trial  • MeiraGTx to host investor conference call on Friday, July 17 at 8:00 a.m. ET     LONDON and NEW YORK, July 17, 2020 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced six-month data from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with genetically confirmed variants in the RPGR gene. Significant...

Continue reading

NKT awarded turnkey order for the on- and offshore project Shetland HVDC Link

Company Announcement17 July 2020Announcement No. 20NKT awarded turnkey order for the on- and offshore project Shetland HVDC LinkNKT has been awarded a contract of approx. EUR 235m (approx. DKK 1.75bn) by SSEN Transmission to deliver and install a high-voltage DC (direct current) interconnector to the Shetland HVDC Link project. The turnkey order comprises the manufacturing of approx. 2×260 km of 320 kV high-voltage DC on-and offshore power cables, installation by the cable-laying vessel NKT Victoria and protection of the cables.NKT President and CEO Alexander Kara says:– This turnkey order confirms NKT’s strong position in the market for high-voltage DC interconnectors. I am very pleased that we are selected as partner for the Shetland HVDC Link, which will provide a sustainable grid connection to Shetland and renewable energy...

Continue reading

NKT er tildelt turnkey ordre til on- og offshore projektet Shetland HVDC Link

Selskabsmeddelelse17. juli 2020Meddelelse nr. 20NKT er tildelt turnkey ordre til on- og offshore projektet Shetland HVDC LinkNKT er blevet tildelt en kontrakt til en værdi af cirka EUR 235 mio. (cirka DKK 1,75 mia.) af SSEN Transmission på levering og installation af en højspændings-kabelforbindelse til jævnstrøm (DC) til Shetland HVDC Link-projektet. Turnkey-ordren omfatter produktion af cirka 2×260 km 320 kV DC on- og offshorekabler, installation med kabeludlægningsskibet NKT Victoria samt beskyttelse af kablerne.NKT CEO Alexander Kara siger:– Denne turnkey-ordre bekræfter NKTs stærke position i markedet for interconnectors baseret på jævnstrøms-højspænding. Jeg er meget tilfreds med at NKT er valgt som partner til Shetland HVDC Link, som betyder at Shetland får en bæredygtig tilslutning til elnettet og at der leveres vedvarende...

Continue reading

Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research

NEWTON, Mass., July 17, 2020 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Cancer Therapy Evaluation Program (CTEP). The CRADA will focus on advancing XPOVIO (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, which blocks the cellular protein XPO1. XPO1 plays a key role in regulating the activity of tumor suppressor proteins and other oncoproteins relevant in cancer cell biology and cancer cell survival. XPO1 may be an important, novel target in the treatment of numerous  cancer types. XPO1 is frequently overexpressed in both hematologic and solid tumors, and the degree of XPO1...

Continue reading

Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit

CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today announced that Christopher Winrow, Ph.D., Senior Director, Neuroscience Development Program Lead, presented on “Leveraging Biomarker Data & Preclinical Models to Guide the Design of Clinical Studies” at the Annual Biomarkers in Alzheimer’s Disease Summit that was held virtually on July 15, 2020.The presentation detailed the application of translational biomarkers to guide clinical activities for IW-6463, the Company’s therapeutic candidate for CNS diseases. In preclinical studies, IW-6463 has demonstrated beneficial effects across four domains relevant to neurodegenerative diseases: cerebral blood flow, cellular bioenergetics,...

Continue reading

DSP Group Inc.’s Second Quarter 2020 Earnings Release and Conference Call

SAN JOSE, Calif., July 17, 2020 (GLOBE NEWSWIRE) — DSP Group® Inc. (NASDAQ:DSPG), will release its earnings results for the second quarter of 2020 on July 30th, 2020 before market opens. The company would like to invite you to participate in a conference call at 8:30 AM ET. DSP Group’s management team will comment on the financial results and press release and be available to answer questions.Investors may access the conference call by dialing +1 877 8709135 (domestic US) or +44 (0) 2071 928338 (international) approximately 10 minutes prior to the starting time. The password is 5493607. A replay of the conference call will be available for a week following the call. To listen to the session, please dial +1 (917) 677-7532, domestically or +44 (0) 3333009785, internationally and enter the company access code: 5493607#

Continue reading

Gran Colombia Reports Second Quarter and First Half 2020 Gold Production; Announces Details for the Forthcoming Second Quarter 2020 Results Webcast

TORONTO, July 17, 2020 (GLOBE NEWSWIRE) — Gran Colombia Gold Corp. (TSX: GCM; OTCQX: TPRFF) announced today that it produced a total of 17,497 ounces of gold in June 2020 bringing the total for the second quarter of 2020 to 48,228 ounces compared with 57,882 ounces in the second quarter of 2019. For the first half of 2020, the Company has produced a total of 104,475 ounces of gold compared with 118,483 ounces in the first half of last year. The second quarter and first half 2020 production results reflect the impact on the Company’s operations of the COVID-19 national quarantine in Colombia invoked on March 25, 2020 and which remains in effect. The Company is continuing to operate at both Segovia and Marmato and expects to update its 2020 annual production guidance when it reports its mid-year financial results in August.Lombardo...

Continue reading

Caldas Gold Reports Second Quarter and First Half 2020 Gold Production; Announces Details for the Forthcoming Second Quarter 2020 Results Webcast

TORONTO, July 17, 2020 (GLOBE NEWSWIRE) — Caldas Gold Corp. (TSX-V: CGC; OTCQX: ALLXF) announced today that it produced a total of 1,435 ounces of gold in June 2020 bringing the total for the second quarter of 2020 to 3,851 ounces compared with 6,257 ounces in the second quarter of 2019. For the first half of 2020, the Company has produced a total of 9,752 ounces of gold compared with 12,472 ounces in the first half of last year. The second quarter and first half 2020 production results reflect the impact on the Company’s operations of the COVID-19 national quarantine in Colombia invoked on March 25, 2020 and which remains in effect. The Company’s Marmato mine and plant are continuing to operate and the Company expects to update its 2020 annual production guidance when it reports its mid-year financial results in August.Lombardo...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.